基于医疗保险索赔数据的结直肠癌筛查方法的最新趋势。
Recent trends in colorectal cancer screening methods based on Medicare claims data.
机构信息
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Department of Health Services Research, Mayo Clinic, Rochester, MN, USA.
出版信息
Curr Med Res Opin. 2021 Apr;37(4):605-607. doi: 10.1080/03007995.2021.1879754. Epub 2021 Feb 18.
OBJECTIVE
Despite the availability of multiple screening modalities for early detection of colorectal cancer (CRC), participation rates remain well below guideline recommendation goals in the United States. This study analyzed and compared recent national trends in utilization of CRC screening modalities using Medicare claims data.
METHOD
Medicare claims data for CRC screening during 2014-2018 were aggregated and analyzed by CPT code frequency. Changes in CRC screening test frequencies during the analysis period were measured generalized linear models and analysis of compound annual growth rates (CAGRs).
RESULTS
Utilization of the mt-sDNA test increased significantly over time (from 2481 claims in 2014 to 335,455 claims in 2018; < .001), in contrast to the other analyzed CRC screening tests. The CAGR was higher for mt-sDNA (166.81%) than for COL (0.52%), FOBT (-11.75%), and FIT (0.67%).
CONCLUSIONS
Utilization of the mt-sDNA test for average-risk CRC screening has increased rapidly since its approval in 2014. These data support growing patient and provider interest in the mt-sDNA test as a non-invasive option for average-risk CRC screening.
目的
尽管有多种筛查方法可用于早期发现结直肠癌（CRC），但美国的参与率仍远低于指南建议目标。本研究使用医疗保险索赔数据分析和比较了最近 CRC 筛查方法的利用情况。
方法
汇总了 2014-2018 年期间 CRC 筛查的医疗保险索赔数据，并按 CPT 代码频率进行分析。在分析期间，通过广义线性模型和复合年增长率（CAGR）分析来衡量 CRC 筛查测试频率的变化。
结果
与其他分析的 CRC 筛查测试相比，mt-sDNA 测试的使用随着时间的推移显著增加（从 2014 年的 2481 项索赔增加到 2018 年的 335455 项索赔；<0.001）。mt-sDNA 的 CAGR 较高（166.81%），而 COL（0.52%）、FOBT（-11.75%）和 FIT（0.67%）较低。
结论
自 2014 年批准以来，用于平均风险 CRC 筛查的 mt-sDNA 测试的使用率迅速增加。这些数据支持患者和提供者对 mt-sDNA 测试越来越感兴趣，将其作为平均风险 CRC 筛查的非侵入性选择。
Zotero 插件